Ginkgo Bioworks has released its q1 2026 earnings transcript, which includes a reported drop in revenue and notes on restructuring efforts. The company's earnings per share missed estimates, but its stock price has seen varying reactions, with some reports indicating a surge and others a slump. The company's financial outlook, including a projected cash burn, appears to be a point of focus for investors.